

# Detailed Table of Contents

	<i>Main Volume</i>	<i>Supple- ment</i>
Foreword to the Third Edition .....	v	—
Preface to the Third Edition .....	vii	v
Acknowledgments.....	ix	viii
Summary Table of Contents.....	xi	ix

## PART I INTRODUCTION

CHAPTER 1 INTRODUCTION.....	3	3
I. The Development of Antifraud Measures .....	3	3
II. Health Care Fraud Prosecutions: A History .....	5	—
III. Structural Defects in the System .....	10	—
A. Inverse Incentives .....	10	—
B. Erosion of Copayments .....	12	—
IV. An Overview of Fraud in Medicare .....	14	—
V. Conclusion and Comment on the Rate of Prosecutions, Convictions, and Exclusions .....	15	3
CHAPTER 2 LITIGATION AND COUNSELING: AN OVERVIEW ....	19	5
I. Litigation in a Complex Environment .....	19	5
A. Investigative Tools.....	19	—
B. Understanding the Regulatory Environment .....	20	5
C. Sanctions.....	21	—
II. Determining the Provider’s Risk and Organizing a Strategic Response .....	23	—
Figure 2-1. Advising the Client: FDA, Patient Abuse, and Referral Issues .....	26	—
Figure 2-2. Advising the Client: Billing and Referral Issues .....	27	—

## PART II THEORIES OF FRAUD LIABILITY IN HEALTH CARE CASES

CHAPTER 3	FALSE BILLING WITHIN THE REIMBURSEMENT RULES OF MEDICARE AND KEY FEDERAL HEALTH CARE PROGRAMS.....	31	9
	I. Introduction.....	32	—
	II. Overview of the Medicare Reimbursement System .....	35	—
	A. Legislative History .....	35	—
	B. The 2010 Changes Relevant to Health Care Fraud Enforcement .....	35	—
	C. Administration and Operation .....	36	—
	D. Structure of Medicare Reimbursement.....	36	—
	III. Medicare Part A in General.....	38	11
	A. Eligibility and Enrollment .....	38	—
	1. The Aged and the Disabled.....	38	—
	2. Uninsured Elderly Individuals .....	38	—
	3. Disabled Individuals .....	39	—
	4. Individuals Exposed to Environmental Health Hazards.....	39	—
	B. Extent of Insurance Coverage Under Part A.....	39	11
	1. Hospital Insurance Coverage .....	40	11
	2. Skilled Nursing Facility Insurance Coverage .....	41	11
	3. Home Health Care Insurance Coverage.....	42	12
	C. Payment of Claims Through Medicare Administrative Contractors .....	44	—
	D. Part A: Reimbursement Methodology .....	46	—
	1. The Early Years: Cost-Based Reimbursement .....	46	—
	2. Prospective Payment System (PPS).....	46	—
	a. Overview of the PPS.....	46	—
	b. Costs Covered by the PPS .....	48	—
	c. Exclusions From the PPS .....	49	—
	i. Hospitals and Hospital Units Not Covered.....	49	—
	ii. Hospital Costs Not Covered.....	50	—
	iii. Other Costs Not Covered .....	50	—
	d. Diagnosis-Related Group Classification Under the PPS.....	51	—
	E. Obligations Required of Nursing Homes .....	51	—
	F. Implications for Counsel: Part A Billing .....	52	—
	IV. Medicare Part B .....	54	12
	A. Eligibility and Enrollment .....	54	12
	B. Extent of Insurance Coverage Under Part B .....	56	—
	1. Coverage in General .....	56	—

	<i>Main Volume</i>	<i>Supple- ment</i>
2. Coverage for Physician Services .....	58	—
3. Coverage for Anesthetic Services .....	59	—
4. Coverage for Certain Diagnostic Tests .....	60	—
5. Coverage for Ambulance Services.....	61	—
6. Coverage for Outpatient Physical Therapy Services and Speech Pathology Services.....	62	—
7. Coverage for Services Provided “Incident to” a Physician’s Services .....	63	—
8. Coverage for Durable Medical Equipment.....	64	—
9. Ambulatory Surgical Centers.....	66	—
C. Payment of Claims Through Medicare Administrative Contractors .....	66	—
D. Implications for Counsel: Part B Billing.....	67	12
1. The 2017 Reimbursement Mechanism Changes [New Topic].....	—	12
V. Medicare Part C .....	68	—
A. Coverage Through an HMO or Managed Care Organization .....	68	—
B. Provision of Care.....	68	—
C. HMO (or MCO) Reimbursement and Opportunities for Fraud .....	69	—
VI. Medicare Part D .....	70	13
A. Development of Medicare Part D.....	70	—
B. Structure of Medicare Part D.....	72	13
1. Enrollment Eligibility .....	72	13
2. Specific Rules Regarding Prescription Drug Plan Sponsors.....	72	—
C. Part D Expenditures [New Topic].....	—	14
VII. Specific Changes Implemented in 2010.....	77	14
A. Program Integrity Modifications .....	77	—
1. Provider Screening.....	77	—
2. Overpayments .....	79	—
B. Transparency Reports .....	80	14
1. Reporting of Things of Value Given to Physicians and Hospitals.....	80	14
2. Reporting Required of Pharmacy Benefit Managers .....	82	—
3. Reporting Required of Nursing Homes .....	83	—
4. Implications for Counsel.....	85	—
C. Release of Program Data .....	86	—
VIII. The Section 340B Program .....	86	—
IX. The Medicaid Programs .....	88	15
A. “Best Price” .....	89	—
B. Payment for Drugs Used Off-Label.....	90	15
C. Miscellaneous Provisions: Required Corporate Integrity Programs.....	91	—
D. Conclusion.....	91	—

	<u>Main Volume</u>	<u>Supple- ment</u>
CHAPTER 4 THE CIVIL FALSE CLAIMS ACT .....	93	17
I. Introduction .....	94	18
II. Background and Application .....	97	—
A. Background .....	97	—
B. False Claims Act Suits and Health Care Fraud .....	99	—
C. Types of Health Care Fraud Schemes Alleged Under the FCA .....	99	—
III. Elements of an FCA Action .....	102	18
A. The Law .....	102	18
1. The Pre-FERA False Claims Act .....	102	—
2. The Post-FERA False Claims Act .....	102	—
3. Comparison of Provisions .....	103	—
4. The Principal Elements .....	105	18
B. Claim .....	106	19
C. Submission of the Claim .....	108	19
D. Falsity of the Claim .....	112	19
1. False Statements .....	112	19
2. False Certifications .....	116	20
3. Knowledge of the Claim’s Falsity .....	119	21
E. <i>Respondeat Superior</i> Liability .....	121	—
F. Damages and Penalties .....	122	—
IV. <i>Qui Tam</i> Provisions of the FCA .....	124	21
A. Basic Procedure .....	125	21
1. Complaint and Disclosure Statement .....	125	21
2. Intervention .....	126	—
3. Declination .....	127	—
4. Dismissal .....	128	22
B. Award to the Relator .....	129	—
C. Whistleblower Protection .....	131	—
1. Pre-FERA Case Law .....	132	—
V. Legal Issues Under the <i>Qui Tam</i> Provisions .....	134	22
A. Public Disclosure Bar .....	134	22
1. The 1986 Amendments .....	134	—
2. The 2010 Amendments .....	136	22
3. Case Law .....	137	23
a. “Public Disclosure” .....	138	23
b. “Allegations or Transactions” .....	141	—
c. “Based Upon” .....	141	—
d. “Original Source” .....	142	—
e. Comment .....	143	—
B. Suits Against States .....	144	23
C. Proceeds of an FCA Case .....	146	—
D. Constitutionality .....	147	—
E. Collateral Estoppel Impact of Prior Guilty Pleas .....	147	—

	<u>Main Volume</u>	<u>Supple- ment</u>
VI. Implications for Counsel .....	148	—
VII. State False Claims Act Statutes.....	149	—
VIII. Conclusion .....	150	—
 CHAPTER 5 THE FEDERAL FOOD, DRUG, AND COSMETIC ACT ...	 151	 25
I. Introduction.....	153	—
A. Potential for Health Care Billing Fraud.....	153	—
B. Liability of Manufacturers.....	154	—
1. Criminal Prosecution .....	154	—
2. Private Litigation .....	157	—
II. Medicare Reimbursement Policies.....	158	—
A. Coverage for New Procedures, Drugs, and Devices .....	158	—
B. Coverage for Investigational Devices.....	162	—
1. Experimental/Investigational (Category A) Devices.....	162	—
2. Nonexperimental/Investigational (Category B) Devices.....	163	—
III. Structure of the Federal Food, Drug, and Cosmetic Act.....	163	27
A. Overview .....	163	—
B. Purpose of the Act .....	164	—
C. Drugs .....	165	27
1. Investigational Use of a New Drug.....	168	—
2. Premarket Approval of Drugs .....	171	27
a. New Drugs.....	171	—
b. Generic Drugs.....	172	27
3. Supplements to an Approved Nonexperimental Drug Application or an Approved Abbreviated Nonexperimental Drug Application.....	174	—
4. Required Records and Reports.....	176	—
D. Medical Devices .....	177	—
1. Classification.....	177	—
a. Class I Devices .....	178	—
b. Class II Devices .....	179	—
c. Class III Devices.....	179	—
d. Classification Panels.....	180	—
2. Premarket Approval .....	180	—
a. Concept of Substantial Equivalence and the 510(k) Process.....	180	—
b. Class III Devices.....	181	—
c. Labeling and Intended Use.....	183	—
3. Determining Safety and Effectiveness.....	184	—
4. Changes to a Device.....	186	—
5. Medical Device Reports.....	188	—

	<i>Main Volume</i>	<i>Supple- ment</i>
E. The Manufacturing of Drugs and Devices .....	189	28
1. The Manufacturing Process .....	190	—
2. The Registration and Inspection Process .....	191	28
3. The “Current Good Manufacturing Practice”(CGMP) Requirements and Vagueness.....	192	—
IV. Prohibited Activities.....	193	28
A. Adulterated Drugs and Devices.....	193	—
1. Manufacturing Problems.....	194	—
2. Additional Adulteration Related to Drugs.....	195	—
3. Additional Adulteration Related to Devices.....	195	—
B. Misbranded Drugs and Devices.....	196	28
C. Prohibitions and Disclosure Obligations Regarding Samples.....	199	—
V. Criminal Prosecutions .....	201	29
A. The Broad Prohibitions Against Adulteration and Misbranding .....	202	29
1. Distribution Prohibitions.....	202	29
2. Manufacturing Prohibitions .....	202	—
3. Wholesale Distribution Prohibitions.....	203	—
4. Prohibitions Regarding Samples.....	204	—
B. The Crimes .....	204	29
1. Misdemeanor Culpability.....	204	—
a. In General .....	204	—
b. Individual Liability.....	207	—
c. Comment .....	209	—
2. Felony Culpability .....	212	—
a. In General .....	212	—
b. Interplay With Securities and Exchange Commission Charges .....	218	—
c. In the Sale of Drug Samples .....	219	—
3. Each Shipment or Sale Is a Separate Crime.....	219	—
4. Charging Issues .....	219	—
5. Off-Label Promotion of Drugs and Devices.....	222	29
a. The Legal Requirements.....	222	—
i. Drugs.....	222	—
ii. Devices.....	224	—
iii. The Concepts of Adulteration and Misbranding .....	224	—
b. The Practice of Medicine.....	225	29
c. Evaluating the Economic Incentives .....	226	—
d. First Amendment Rights of Drug and Device Manufacturers.....	227	—

	<u>Main Volume</u>	<u>Supple- ment</u>
i. FDA Guidance and the Passage of the Food and Drug Administration Modernization Act of 1997 (FDAMA)...	232	—
ii. The FDAMA Safe Harbor.....	234	—
e. False Claims Act Liability for Off-Label Prescriptions.....	236	—
f. Collateral Consequences of Off-Label Promotion.....	236	—
g. Implications for Counsel .....	237	—
6. Importation of Drugs.....	238	—
C. Commencement of Criminal Proceedings.....	240	—
1. Section 305 Proceedings .....	240	—
2. Grand Jury Investigations .....	242	—
VI. Debarment and Suspension.....	242	—
VII. Miscellaneous Matters Not Covered.....	243	—

**PART III THE ANTI-KICKBACK STATUTE, STARK  
PROHIBITIONS, AND ANTI-KICKBACK ADVISORY OPINIONS**

CHAPTER 6 THE ANTI-KICKBACK STATUTE AND RELATED SAFE HARBORS .....	247	33
I. Introduction.....	249	—
II. The Anti-kickback Statute: An Overview .....	249	—
A. Legislative History .....	249	—
B. Purpose of the Statute .....	251	—
C. The Prohibitions: An Overview.....	252	—
D. The Safe Harbors: An Overview .....	253	—
E. Void-for-Vagueness Challenges.....	253	—
F. Practical Implications for Counsel .....	254	—
III. Elements of the Anti-kickback Statute.....	255	35
A. The Criminal Prohibitions .....	255	—
B. Remuneration .....	258	35
1. Remuneration Defined .....	258	—
2. Examples of Remuneration.....	260	35
3. Business Relationship Between Payer and Payee .....	264	—
a. General Agreements .....	264	—
b. Joint Ventures .....	264	—
4. Purpose of the Payments.....	266	35
a. The Applicable Legal Standard .....	266	—
b. Expressions of Purpose.....	270	—
C. Inducement .....	272	—
D. “Knowingly and Willfully” .....	273	36
1. Debate Surrounding the Terms .....	273	—

	<i>Main Volume</i>	<i>Supple- ment</i>
2. <i>United States v. Starks</i> .....	276	36
E. “Directly or Indirectly” and “Overtly or Covertly”...	277	—
IV. The Exceptions to the Anti-kickback Statute Prohibitions and the Safe Harbor Regulations.....	277	37
Table 6.1. Referral Restrictions: Overlapping Exceptions and Safe Harbors.....	279	—
Table 6.2. Safe Harbor Treatment in OIG Anti-kickback Advisory Opinions.....	283	—
A. Discounts .....	286	—
1. In General.....	286	—
2. Restrictions .....	289	—
a. Restrictions on the Statutory Exception .....	289	—
b. Restrictions on the Regulatory Safe Harbor.....	289	—
3. Practice Pointers.....	292	—
B. Employee Bonuses .....	293	37
C. Payments to Group Purchasing Agent.....	294	—
D. Waiver of Coinsurance .....	296	—
E. Risk-Sharing Arrangements.....	297	—
1. The Statutory Exception .....	297	—
2. Increased Coverage, Reduced Cost-Sharing Amounts, or Reduced Premium Amounts Offered by Health Plans to Enrollees.....	299	—
3. Price Reductions Offered to Health Plans by Contract Providers .....	300	—
4. Price Reductions Offered to Eligible Managed Care Organizations.....	302	—
5. Price Reductions Offered by Contractors With Substantial Financial Risk to Managed Care Organizations.....	305	—
6. Comment on These Safe Harbors .....	308	—
F. Investment Interests.....	308	—
1. Large, Publicly Traded Entities.....	309	—
2. Small Entities With Active and Passive Investors .....	310	—
3. Small Entities, With Active and Passive Investors, in an Underserved Area.....	311	—
4. Investments in Group Practices .....	311	—
5. Ambulatory Surgical Centers (ASCs).....	312	—
a. Surgeon-Owned, Single-Specialty, and Multispecialty ASCs.....	312	—
b. Hospital/Physician ASCs.....	314	—
c. Comment .....	314	—
G. Lease of Space and Equipment Rental .....	315	—
1. Lease of Space .....	315	—
2. Equipment Rental.....	316	—



	<u>Main Volume</u>	<u>Supple- ment</u>
H. Personal Services and Management Contracts.....	317	37
I. Sale of Practice .....	319	—
J. Referral Services .....	321	—
K. Warranties.....	322	—
L. Practitioner Recruitment.....	324	—
M. Obstetrical Malpractice Insurance Subsidies.....	325	—
N. Cooperative Hospital Service Organizations.....	326	—
O. Referral Arrangements for Specialty Services.....	326	—
P. Ambulance Supply Replenishment .....	327	—
Q. Waiver of Coinsurance by Pharmacies Under Medicare Part D.....	328	—
R. Rural Health Centers in Medically Underserved Areas.....	329	—
S. Electronic Prescribing Items and Services .....	329	—
T. Electronic Health Records Items and Services.....	331	—
V. Sanctions .....	332	—
A. 42 U.S.C. §1320a-7a(a)(5) .....	333	—
B. 42 U.S.C. §1320a-7a(a)(7) .....	334	—
C. 42 U.S.C. §1320a-7a(b).....	335	—
VI. State Statutes.....	335	—
VII. Implications for Counsel.....	337	—
 CHAPTER 7 THE STARK PROHIBITIONS AND RELATED SAFE HARBORS .....	 339	 39
I. Introduction.....	340	—
II. Scope of the Stark Prohibitions.....	343	—
A. “Referral” .....	345	—
B. “Designated Health Services” .....	346	—
C. “Financial Relationship” .....	347	—
D. “Remuneration”.....	350	—
III. The Stark Safe Harbors .....	352	40
A. Safe Harbors Relating to Ownership and Investment Interests.....	353	—
1. Publicly Traded Securities and Mutual Funds .....	355	—
2. Hospitals in Puerto Rico, Rural Entities, and Certain Hospitals.....	356	—
B. Safe Harbors Relating to Compensation Arrangements .....	357	—
1. Rental of Office Space and Equipment .....	358	—
2. Bona Fide Employment Relationships and Personal Service Arrangements.....	360	—
3. Hospital Remuneration .....	363	—
4. Physician Recruitment .....	363	—
5. Isolated Transactions.....	366	—

	<u>Main Volume</u>	<u>Supple- ment</u>
6. Arrangements Between Hospitals and Physician Group Practices .....	366	—
7. Payments by a Physician for Items and Services .....	367	—
8. Nonmonetary Compensation up to \$300 .....	368	—
9. Fair-Market-Value Compensation.....	368	—
10. Medical Staff Incidental Benefits, Risk-Sharing Agreements, and Compliance Training.....	369	—
11. Indirect Compensation Arrangements.....	370	—
C. Safe Harbors Relating to Both Ownership and Investment Interests and Compensation Arrangements .....	371	41
1. Physician Services Provided in a Group Practice.....	371	—
2. In-Office Ancillary Services.....	372	41
3. Prepaid Health Plans .....	373	—
4. Certain Clinical Laboratory Services.....	374	—
5. Academic Medical Centers .....	374	—
6. Implants in Ambulatory Surgical Centers.....	375	—
7. Erythropoietin and Other Dialysis-Related Outpatient Prescription Drugs.....	375	—
8. Preventive Screening Tests, Immunizations, and Vaccines.....	376	—
9. Eyeglasses and Contact Lenses Following Cataract Surgery.....	376	—
D. Additional Miscellaneous Safe Harbors .....	377	—
1. Referral Services .....	377	—
2. Obstetrical Malpractice Insurance Subsidies ...	377	—
3. Professional Courtesy .....	378	—
4. Retention Payments in Underserved Areas.....	378	—
5. Communitywide Health Information Systems .....	378	—
6. Electronic Prescribing Items and Services.....	379	—
7. Electronic Health Records Items and Services .....	379	—
IV. Reporting Requirements and Disclosure Protocols .....	380	—
V. Penalties .....	382	—
A. Refund for Prohibited Services .....	382	—
B. Penalty for Each Billed Service.....	382	—
C. Penalty for Each Prohibited Referral Arrangement .....	383	—
D. Penalty for Failing to Identify Prohibited Referral Arrangements.....	383	—
E. Cumulative Effect of Penalties .....	383	—
VI. Advisory Opinions .....	384	41

	<u>Main Volume</u>	<u>Supple- ment</u>
CHAPTER 8 THE ANTI-KICKBACK ADVISORY OPINIONS .....	385	43
I. Introduction .....	391	—
II. The Advisory Opinion Process .....	392	—
A. Requesting an Advisory Opinion .....	392	—
1. Subject Matter .....	392	—
2. Required Contents .....	394	—
3. Consultation With Department of Justice and U.S. Attorneys’ Offices .....	395	—
4. Time Frame for Response .....	396	—
B. Effect of an Advisory Opinion .....	396	—
C. Other Considerations .....	398	—
1. Legal Considerations .....	398	—
2. Advisory Letters Issued by the Health Care Financing Administration in the 1970s .....	399	—
3. The Entrapment-by-Estoppel Defense .....	400	—
III. The Advisory Opinions .....	400	50
A. Arrangements That Affect Medicare or Medicaid Program Beneficiary Payment Obligations .....	403	51
1. Grant Programs to Fund Patient Copayments .....	403	51
a. Donor-Blind, Disease-Specific Grant Programs Run by Independent Charities .....	404	51
i. Implications for Counsel .....	408	—
b. Donor-Specific Programs by Pharmaceutical Companies for Patients Using Only Company Drugs .....	408	—
i. Implications for Counsel .....	409	—
2. Programs to Pay Dialysis Patients’ Premiums .....	410	—
a. Implications for Counsel .....	411	—
3. Waiver of Facility Copayments for All Company Retirees .....	411	—
a. Implications for Counsel .....	412	—
4. Waiver of Copayments Through “Coordination of Benefits” Between a Nursing Home and a Health Plan .....	413	—
a. Implications for Counsel .....	415	—
5. Waiver of Patient Copayments and Deductibles for Clinical Trials .....	415	52
a. Clinical Trial of Experimental Surgical Procedure .....	416	—
b. NIH-Sponsored Clinical Trials .....	417	—
c. CMS-Sponsored Clinical Trials .....	418	—
d. Public Health Service–Funded Clinical Trial [New Topic] .....	—	52

	<u>Main Volume</u>	<u>Supple- ment</u>
e. Implications for Counsel [Renumbered Topic (Formerly III.A.5.d.)] .....	418	52
6. Waiving Copayment Obligations for Program Beneficiaries Receiving Emergency Ambulance Services.....	418	—
a. By Not-for-Profit Ambulance Provider With a Negligible Market Share .....	419	—
b. For Municipal or County Residents Receiving Emergency Ambulance Services...	420	—
c. By Hospital to Ensure Transportation of Patients From Referral Sources .....	422	—
d. Implications for Counsel .....	422	—
7. Waiver of Copayments for Profoundly Ill Patients.....	422	—
a. Implications for Counsel .....	423	—
8. Waiver of Copayments to Support a Preexisting Program Promoting Health Care.....	423	—
a. Implications for Counsel .....	424	—
9. Waiver of Copayments for Medicare Part D Beneficiaries.....	424	53
10. Waiver of Copayments for Patients from an Indian Tribe.....	425	—
11. Waiver of Copayments for Services by a Breast Cancer Center .....	425	—
a. Implications for Counsel .....	426	—
12. Waiver of Premiums and Copayments in the Delivery of Managed Care.....	426	53
13. Waiver of Coinsurance for Dual-Eligible Nursing Home Residents .....	427	—
14. Year-End Percentage Rebate Payment by a Retailer to Pharmacy Customers.....	428	—
15. Discounting Patient Deductibles.....	429	53
16. Charging a Lower Rate to Patients Whose Costs Are Covered by a State-Run Veterans' Board .....	429	—
17. Discounting Part A Hospital Inpatient Deductibles .....	430	53
B. Arrangements That Involve the Provision of Free Supplies, Services, or Gifts to Referral Sources .....	431	54
1. Providing Free Services and Items of Care to Program Beneficiaries.....	431	54
a. Free Transportation Services to Patients .....	431	54
b. Free Vision Screening Tests for Infants.....	433	—
c. Free On-Site Screening Services as Part of a Telemedicine Network.....	433	—

	<u>Main Volume</u>	<u>Supple- ment</u>
d. Free Ambulance Services to Indigent Patients.....	434	—
e. Provision of Free Items by Home Health Agencies.....	435	—
f. Gifts by Durable Medical Equipment Suppliers.....	435	—
g. Free Drugs Provided to Patients Through Patient Assistance Plans.....	437	—
h. Free Care Provided to End-Stage Renal Disease Patients.....	440	—
i. Free Lodging and Meals for Medicaid Program Beneficiaries [Revised Heading (Formerly “Free Post-surgery Hotel Stay for Medicaid Program Beneficiaries”)].....	440	54
j. Free Vaccine Reminder Program for Patients Covered by Fee-for-Service Federal Health Programs.....	441	—
k. “Frequent Flyer” and Discount Coupon Programs.....	441	55
l. Free Diapers and Play Yards to At-Risk Mothers and Infants.....	442	—
m. Free Magnetic Resonance Imaging for Financially Needy Patients.....	442	—
n. Implications for Counsel.....	443	—
2. Remuneration Arrangements Involving Ambulance Providers.....	443	—
a. Hospital Gift of an Ambulance to a Municipality.....	444	—
i. Comment.....	445	—
b. “Pay to Play” Payments by Ambulance Companies to Local Governments.....	445	—
c. Equipment Leased at a Nominal Charge to Ambulance Companies.....	447	—
d. In-Kind Swap of Services Between an Ambulance Provider and a Municipality.....	448	—
3. Provision of Free Pharmacy Services to Hospital Organ Transplant Centers.....	448	—
a. Implications for Counsel.....	449	—
4. Kickback Implications of a Charitable Gift From a Hospital to a Referral Source, Whether a Physician, Medical School, or Another Hospital.....	449	—
a. Implications for Counsel.....	452	—
5. Exchanging Free Podiatry Services for Access to Shoe Retailer Customers.....	453	—
a. Implications for Counsel.....	455	—

	<u>Main Volume</u>	<u>Supple- ment</u>
6. Providing Free Employees to Potential Referral Sources.....	455	—
a. Free Psychiatric Residents Provided by Hospitals to a Charitable Coalition.....	456	—
b. Free Lab Assistants Provided by a Laboratory Company to Dialysis Facilities ..	457	—
c. Implications for Counsel .....	457	—
7. Free Goods and Services Among Referral Participants in a Telemedicine Network .....	458	—
8. Free Care and Services Provided by a Hospice to Referral Sources .....	458	—
a. Implications for Counsel .....	459	—
9. Gifts From a Hospital to Other Institutional Providers .....	460	—
a. Hospital Gifts to a Hospice.....	460	—
b. Hospital Gifts to a Nursing Home .....	461	—
10. Free Items Provided by Durable Medical Equipment Suppliers.....	461	—
11. Transfer of Money From a State Authority to Medical Education and Research Funds .....	462	—
12. Free Supplies and Services Provided by a Laboratory to Referral Sources.....	463	55
13. Benefits Investigations Provided to Referral Sources.....	463	—
14. Pharmacy Services Provided to Community Homes .....	465	—
15. Placement Agency Receiving Compensation for Referral of New Residents to Senior Communities .....	466	—
16. Provision of Free Vaccine Storage Equipment to Physicians [New Topic].....	—	55
C. Arrangements That Involve Discounts, Financial Incentives, the Provision of Services, or Other Business Transactions Between Providers and Referral Sources .....	466	56
1. Joint Ventures (Other Than Ambulatory Surgical Centers).....	466	—
a. Between Hospitals and Potential Referral Sources (Other Than Ambulance Providers)...	467	—
i. Implications for Counsel.....	470	—
b. Joint Ventures for Magnetic Resonance Imaging Centers.....	471	—
c. Joint Venture Ambulance Services .....	472	—
d. Joint Physician Investment and Cross-Referrals to a Physical Therapy Center .....	474	—

	<u>Main Volume</u>	<u>Supple- ment</u>
e. Joint Venture Pathology Laboratory Company.....	474	—
f. Joint Venture Pediatric Psychiatric Day Treatment Facility.....	475	—
g. Joint Venture Imaging Clinic in a Medically Underserved Area .....	475	—
h. Joint Venture Rural Medical Practice .....	476	—
i. Joint Venture Between an Independent Provider Association and a Managed Care Organization .....	476	—
i. Implications for Counsel.....	478	—
j. Joint Venture Between a “Constitutional” University and Affiliated Entities .....	478	—
k. Joint Venture Long-Term-Care Pharmacy... ..	478	—
2. Ambulatory Surgical Centers (ASCs).....	479	—
a. ASC Between Orthopedic Surgeons and Anesthesiologists .....	479	—
i. Implications for Counsel.....	481	—
b. ASCs Between Hospitals and Physicians....	481	—
i. Implications for Counsel.....	485	—
c. Physician-Owned ASCs.....	485	—
d. Management Fees.....	486	—
3. Arrangements Between Hospitals and Physicians or Physician Groups (Not Involving Joint Ventures).....	486	56
a. Sharing Profits Resulting From Cost-Cutting Between Hospitals and Physicians .....	487	56
b. Physician Recruitment Payments by Hospitals .....	490	—
c. Hospital Payments for On-Call Emergency Services Coverage .....	491	—
4. The Orthopedic Consignment and Loaner Program.....	492	—
a. Implications for Counsel .....	495	—
5. Discount Pharmaceutical Arrangement.....	495	—
a. Implications for Counsel .....	497	—
6. Discounted Ambulance Services Bundled With Services Paid for by Medicare .....	497	—
a. Implications for Counsel .....	499	—
7. Bundled Pricing in the Sale of Mattresses to Skilled Nursing Facilities.....	500	—
8. Business Arrangements and Patient Referrals Between Physicians .....	501	—
a. Ophthalmologists and Optometrists .....	501	—
i. Implications for Counsel.....	502	—

	<u>Main Volume</u>	<u>Supple- ment</u>
b. Oncologists and Urologists.....	503	—
c. Anesthesiologists and Psychiatrists.....	504	—
9. Podiatry Network Assuming an Employer’s Copayment Obligations for Supplemental Coverage .....	504	—
10. Network Payments for Provider Referrals.....	505	—
11. Payment for Referral of Patients for Housing, Including Nursing Homes .....	506	—
12. Insurance Guarantee Plan for an Injectable Pharmaceutical.....	507	—
a. Implications for Counsel .....	508	—
13. Referral Arrangement Between a Hospice and a Nursing Home for Dual-Eligible Individuals.....	508	56
14. Durable Medical Equipment Supplier’s Discount Practices.....	510	—
15. Arrangements That Involve Internet Advertising.....	511	—
a. Implications for Counsel .....	513	—
16. Durable Medical Equipment Supplier’s Contract With Independent Diagnostic Testing Facilities .....	513	—
17. Arrangements Including Investment by a Referral Source in a Provider.....	514	—
18. Pharmaceutical Program Offering Services to Hospitals to Reduce Readmissions .....	514	—
19. Gift of Patient Management Software by a Pharmaceutical Company to a Medicare Advantage Plan and Associated Hospital System [New Topic].....	—	57
D. Miscellaneous Opinions .....	515	57
1. Arrangements That Establish Price or Service Differentials in the Care Provided to Federal Program Beneficiaries Versus Privately Insured Patients.....	515	—
a. Charging Higher Prices to Medicare Program Beneficiaries.....	515	—
i. Implications for Counsel.....	516	—
b. Swapping Discounted Nonfederal Business for Nondiscounted Federal Business.....	516	—
i. Implications for Counsel.....	518	—
2. Giving Something of Value in Absence of an Ability to Make Referrals .....	519	—
3. Incentives Offered to Employees in a Collective Bargaining Agreement.....	520	—



	<u>Main Volume</u>	<u>Supple- ment</u>
4. Group Purchasing Organizations (GPOs).....	520	57
a. GPO Safe Harbor Applied to Electricity Purchases .....	520	—
b. GPO Ownership of Members .....	521	—
c. GPO Offer of Equity Ownership to Members in Lieu of Administrative Fees.....	522	—
d. Purchase of Shares From Other Members [New Topic].....	—	57
5. Outpatient Pharmacy Program Implemented Under the Veterans Health Care Act .....	522	—
6. Contribution by a Pharmaceutical Company to a Charitable Organization .....	523	—
7. Marketing Programs.....	523	—
a. Management and Marketing Services for a Physician-Owned Clinic .....	523	—
i. Implications for Counsel.....	525	—
b. “White Coat” Marketing Program.....	525	—
c. Incentives Offered to Induce Physicians to Complete Marketing Surveys.....	526	—
d. Incentives Offered by a Long-Term-Care Facility to Current Residents to Recommend New Residents.....	526	—
8. Percentage Payments to Consultants Reviewing Provider Billings.....	527	—
a. Implications for Counsel .....	527	—
9. Payments to Employees and Independent Contractors.....	528	—
a. Payments to Referring Physicians by a Nursing Home.....	528	—
b. Purchase of a Clinic as a Condition of Employment.....	528	—
c. Sharing Credit Card Frequent Use Points With Employees.....	528	—
d. Incentive Payments to an Independent Manufacturer’s Representative.....	529	—
i. Implications for Counsel.....	530	—
e. Payments to Part-Time Physicians .....	530	—
10. Golf Tournament Paid for by Referral Sources.....	530	—
a. Implications for Counsel .....	531	—
11. Warranty on a Bundled Product.....	531	—
a. Implications for Counsel .....	533	—
12. Employment of Excluded Individuals .....	533	—
a. Employment of an Excluded Physician in a Nontreatment Role.....	534	—

	<u>Main Volume</u>	<u>Supple- ment</u>
b. Employment of an Excluded Physician for Business Development.....	534	—
c. Comment .....	535	—
d. Transfer of an Excluded Individual’s Invention to an Independent Corporation .....	535	—
13. Providing Money Back or Replacement Product in the Event of Spoilage or Failure of Insurance Coverage [Revised Heading (Formerly “Automatic Refund in the Event of Denial of Medicare Coverage”)] .....	536	58
14. Business Reorganization .....	536	—
15. “Per Patient,” “Per Click,” and “Per Order” Management Fees .....	537	—
16. Malpractice Insurance Subsidy by a Hospital to Specific Individual Physicians .....	538	—
17. Providing Online Services .....	538	—
a. Online Marketing Services Providing Referral Opportunities .....	538	—
b. Free Online Interface Provided by Hospital to Physicians .....	539	—
IV. Conclusion .....	539	—
Appendix to Chapter 8 .....	541	59
Table 8.1. Index to Advisory Opinions by Health Care Industry Sector .....	541	—
Table 8.2. Summaries of Proposals in Anti-kickback Advisory Opinions Released on or After March 26, 2013 .....	550	59

#### **PART IV THE INVESTIGATION AND CHARGING DECISION**

CHAPTER 9 THE INVESTIGATION .....	557	63
I. Introduction .....	559	—
A. The Prosecutor’s Perspective.....	559	—
B. The Defense Perspective .....	560	—
II. Civil Versus Criminal Enforcement .....	562	—
A. The Rise and Fall of <i>Halper</i> .....	563	—
B. <i>Qui Tam</i> Provisions.....	564	—
C. Grand Jury Secrecy.....	565	—
D. Parallel Proceedings .....	566	—
III. Investigative Tools and Techniques .....	567	65
A. Audit Data and Analysis .....	568	65
1. Audit Data .....	568	—
2. Audit Analysis.....	568	65
B. Subpoenas for Documents and Other Items .....	570	65

	<i>Main Volume</i>	<i>Supple- ment</i>
1. Types of Subpoenas .....	572	65
a. Grand Jury Subpoenas .....	572	—
i. Subpoena Duces Tecum Request .....	573	—
ii. Secrecy .....	574	—
b. Inspector General Subpoenas .....	576	—
i. Authority to Obtain Information; Scope of Subpoena.....	577	—
ii. Secrecy .....	579	—
iii. Enforcement.....	579	—
c. Administrative Subpoenas in Criminal Health Care Fraud Cases .....	580	65
i. Appealability.....	582	—
ii. Enforcement of Administrative Subpoenas .....	583	65
d. Administrative Subpoenas to Institutions Under Investigation .....	583	—
e. Civil Investigative Demands Under the False Claims Act.....	584	—
2. Responding to a Subpoena.....	585	—
a. Time for Production.....	587	—
b. Form of Production.....	587	—
c. Burdensomeness Challenges .....	588	—
C. Privileges .....	590	—
1. Attorney-Client Privilege.....	591	—
a. Availability of the Privilege.....	592	—
b. Assertion of the Privilege .....	593	—
c. Waiver of the Privilege .....	594	—
d. The Crime-Fraud Exception .....	596	—
2. Fifth Amendment Privilege.....	598	—
3. Psychotherapist-Patient Privilege .....	598	—
4. Peer Review Privileges .....	601	—
5. Department of Labor Evidentiary Privilege and Confidential Communications.....	601	—
D. Confidentiality Issues .....	602	—
1. Confidentiality of Alcohol and Drug Abuse Patient Records .....	602	—
2. Patient Confidentiality Under State Law .....	606	—
3. Confidentiality Under HIPAA.....	606	—
a. Purpose of the Rules.....	607	—
b. Structure of the Regulations: The Prohibition .....	608	—
i. “Covered Entity”.....	608	—
ii. “Business Associate”.....	609	—
iii. “Protected Information”.....	610	—
c. Structure of the Regulations: Exceptions to the Rule and Other Requirements.....	610	—

	<u>Main Volume</u>	<u>Supple- ment</u>
d. Limitation on the Scope of the Regulations .....	612	—
e. Relevant Permitted and Required Uses and Disclosures.....	613	—
i. Disclosures by Whistleblowers.....	613	—
ii. Disclosures to Health Oversight Agencies and Law Enforcement .....	614	—
f. Interaction With the Food, Drug, and Cosmetic Act.....	617	—
g. Marketing.....	617	—
i. Implications for Counsel.....	619	—
E. Search Warrants .....	620	66
1. Probable Cause.....	624	—
2. Execution of the Warrant .....	627	—
a. Potentially Privileged Materials at the Search Site .....	629	—
b. Computers at the Search Site.....	630	—
c. Access to Patient and Financial Records.....	633	—
3. Photographs and Video Recordings .....	633	—
4. Interviews.....	634	—
5. Length of Search .....	634	—
6. Rule 41 Motion .....	634	—
7. Standing to Challenge a Search .....	635	—
8. Consent to a Search.....	637	66
F. Administrative Searches .....	637	—
G. Trash Runs .....	638	—
H. Obtaining Documents From Witnesses .....	639	—
I. Witness Testimony.....	639	—
1. Contacting Represented Persons or Parties.....	641	—
2. Grand Jury Testimony.....	643	—
3. <i>Qui Tam</i> Relators .....	645	—
4. Civil Investigative Demands.....	645	—
J. Recordings .....	646	—
1. Consensual Recordings.....	646	—
2. Wiretaps and Interceptions.....	647	—
IV. Conclusion .....	649	—
CHAPTER 10 THE CHARGING DECISION .....	651	67
I. Introduction.....	652	69
II. Statutory Offenses .....	654	69
A. Title 18 Offenses: Relevant Conspiracy Statutes....	656	—
1. 18 U.S.C. §1349.....	656	—
2. 18 U.S.C. §371.....	656	—
a. The Purpose or Objects of the Conspiracy.....	657	—

	<i>Main Volume</i>	<i>Supple- ment</i>
b. Manner and Means of the Conspiracy .....	659	—
c. Overt Acts .....	660	—
d. Strategic Opportunities for the Prosecution .....	660	—
B. Title 18 Offenses Involving Fraud Schemes.....	662	69
1. Mail Fraud, 18 U.S.C. §1341 .....	663	—
2. Wire Fraud, 18 U.S.C. §1343.....	668	—
3. Health Care Fraud, 18 U.S.C. §1347 .....	669	69
a. Purpose of the Statute .....	670	—
b. “Willfully” .....	671	—
c. “Executes or Attempts to Execute” .....	671	—
d. “Scheme or Artifice to Defraud” .....	672	—
e. “In Connection With the Delivery” .....	674	—
f. “Affecting Commerce” .....	674	—
g. Vagueness Challenge .....	675	—
h. Enhanced Penalties for Bodily Injury and Death.....	676	69
i. Implications for Counsel .....	677	—
C. Title 18 Offenses Involving False Claims and False Statements .....	678	—
1. False Claim to the United States, 18 U.S.C. §287, and the Related Conspiracy Statute, 18 U.S.C. §286.....	678	—
a. 18 U.S.C. §287 .....	678	—
b. 18 U.S.C. §286 .....	683	—
2. False Statements to the United States, 18 U.S.C. §1001 .....	684	—
3. False Statements Relating to Health Care Matters, 18 U.S.C. §1035 .....	686	—
4. False Statements Regarding Multiple-Employer Welfare Arrangements, 29 U.S.C. §1149.....	688	—
D. Title 18 Offenses Involving Theft or Bribery .....	688	70
1. Theft or Bribery Concerning Programs Receiving Federal Funds, 18 U.S.C. §666.....	688	—
2. Theft or Embezzlement in Connection With Health Care, 18 U.S.C. §669.....	692	70
3. Public Money, Property, or Records, 18 U.S.C. §641 .....	693	—
E. Money Laundering Offenses, 18 U.S.C. §§1956 and 1957 .....	694	—
F. Title 18 Offenses Involving Obstruction of Audits and Investigations.....	697	70
1. Obstruction of Agency Investigations, 18 U.S.C. §§1505 and 1503.....	697	—
2. Obstruction of Criminal Investigations, 18 U.S.C. §1510.....	699	—

	<u>Main Volume</u>	<u>Supple- ment</u>
3. Obstruction of Federal Audits, 18 U.S.C. §1516.....	699	70
4. Obstruction of Criminal Investigations of Health Care Offenses, 18 U.S.C. §1518.....	700	—
G. Offense Traditionally Charged Under Title 21 .....	701	—
1. Unlawful Distribution of a Controlled Substance, 21 U.S.C. §841(a)(1) .....	701	—
H. The Title 42 Medicare/Medicaid Fraud Statutes ....	704	—
1. Making or Causing to Be Made False Statements or Representations, 42 U.S.C. §1320a-7b(a).....	705	—
2. The Medicare/Medicaid Anti-kickback Statute, 42 U.S.C. §1320a-7b(b).....	708	—
3. False Statements or Representations With Respect to Condition or Operation of Institutions, 42 U.S.C. §1320a-7b(c) .....	710	—
4. Illegal Patient Admittance and Retention Practices, 42 U.S.C. §1320a-7b(d).....	711	—
5. Violation of Assignment Terms, 42 U.S.C. §1320a-7b(e).....	711	—
6. Wrongful Disclosure of Individually Identifiable Health Information Under HIPAA, 42 U.S.C. §1320d-6.....	712	—
a. “In Violation of This Part”.....	712	—
b. Felony Intent.....	713	—
I. Criminal Forfeiture Involving Health Care Offenses .....	714	70
1. Criminal Forfeiture, 18 U.S.C. §982(a)(7) .....	714	70
III. Special Statute of Limitations.....	716	—
IV. Implications for Counsel.....	717	—
Figure 10-1. Assessing Criminal Health Care Fraud Charges.....	718	—

## PART V SETTLEMENT AND LITIGATION

CHAPTER 11 GLOBAL RESOLUTIONS .....	723	73
I. Introduction.....	724	—
II. Overview of Global Resolutions.....	725	74
A. Determining the Government’s Case.....	726	—
B. Approaching the Government .....	727	74
1. Civil Investigations.....	727	—
2. Criminal Investigations.....	729	—
3. Deferred Prosecutions.....	730	74
4. Program Exclusion.....	732	74
a. Mandatory Exclusion.....	732	—

	<i>Main Volume</i>	<i>Supple- ment</i>
b. Permissive Exclusion.....	733	74
5. Civil Monetary Penalties.....	736	—
III. Negotiating a Global Resolution.....	737	75
A. Individual Defendants .....	739	—
B. Corporate Defendants .....	741	75
1. Criminal Resolutions .....	741	75
2. Civil Resolutions.....	746	—
3. Corporate Integrity Agreements.....	747	—
4. Corporate Compliance Plans.....	748	76
C. Administrative Exclusion .....	750	—
D. Other Administrative Sanctions.....	752	—
E. Exposure to State Criminal Charges and Civil Liability .....	753	—
F. Other Potential Consequences .....	755	—
IV. Global Settlements Exceeding \$1 Million .....	756	77
Table 11.1. Number and Amounts of Settlements in Four-Year Intervals.....	758	77
Table 11.2. Frequency of Settlements (1991–2018) ....	759	78
V. Conclusion .....	761	—
Table 11-A. Health Care Fraud Settlements of at Least \$1 Million (January 1, 1991–July 1, 2018)..... <i>See Appendix G</i>		
CHAPTER 12 CRIMINAL TRIAL.....	763	79
I. Introduction.....	764	—
II. Trial Strategy.....	765	80
A. Prosecution Theory.....	765	—
B. Defense Theory.....	768	—
C. Practice Pointers .....	770	81
1. Overview.....	770	—
2. The Pretrial Skirmishing .....	772	—
3. The Post-Guilty-Verdict Motion for a New Trial or for Acquittal .....	775	—
4. Particular Cases.....	777	81
a. An Unsuccessful Defense: The Regulations Were Too Ambiguous .....	777	—
b. A Successful Defense: Defendant’s Interpretation of the Regulation Was Reasonable.....	779	—
c. Prosecution Focus on Defendant’s Intent to Defraud Amid Confusing Rules .....	780	—
d. Conflicting Expert Interpretations of the Governing Regulation.....	781	—
e. Intent to Cheat Versus “My Interpretation Must Be Reasonable Because Everyone Is Doing It” .....	782	—

	<u>Main Volume</u>	<u>Supple- ment</u>
f. “Greedy Doctor Performing Unnecessary Surgeries” Versus “Kind, Caring Practitioner” .....	784	—
g. Defining “Intended Use” and Applying the First Amendment to the Food, Drug, and Cosmetic Act [New Topic].....	—	81
h. The Anti-kickback Statute and Willful Blindness [New Topic].....	—	82
III. Common Evidentiary Issues .....	786	84
A. Medical Experts .....	789	—
B. Billing and Regulatory Experts .....	790	—
1. Billing Experts .....	790	—
2. Regulatory Experts.....	792	—
C. Audit Data .....	794	84
1. In General.....	794	—
2. Presenting Audit Data .....	795	84
a. Billing Information .....	795	—
b. Statistical Inferences.....	797	—
i. Statistical Profiles.....	797	—
ii. Statistical Sampling.....	799	—
c. Summary Charts .....	800	84
D. Evidence of Past Regulatory Violations and Global Settlements.....	803	—
IV. Common Defenses and Rebuttals .....	804	—
A. The Lack of Knowledge or Intent Defense .....	804	—
1. The Provider Was Unaware .....	805	—
2. Rules and Regulations Are Ambiguous, Complex, or Confusing.....	810	—
3. Risks Associated With Asserting the Lack of Knowledge or Intent Defense .....	813	—
B. The “Happy Patient” Defense.....	814	—
1. Evidence That the Alleged Fraud Did Not Occur.....	814	—
2. Evidence to Determine the Scope of the Fraud .....	815	—
3. Evidence on the Medical Necessity of the Services .....	815	—
C. The Entrapment-by-Estoppel Defense.....	816	—
V. Jury Instructions .....	818	—
A. The Good-Faith Instruction .....	819	—
B. The Conscious Avoidance Instruction .....	822	—
C. The “Results in Death” Instruction.....	825	—
VI. Conclusion .....	826	—



	<u>Main Volume</u>	<u>Supple- ment</u>
CHAPTER 13 SENTENCING.....	829	85
I. Introduction.....	830	—
II. The Federal Sentencing Process .....	833	—
A. Scheduling and the Presentence Report .....	833	—
B. Notice of Issues and the Sentencing Hearing .....	833	—
III. The Sentencing of Individuals .....	837	86
A. Sentence Enhancements .....	839	86
1. Loss Enhancement .....	839	86
a. Loss and Unlicensed Providers.....	844	—
b. Loss and Relative Culpability.....	846	—
c. Loss and the Identity of the Victim .....	848	—
d. Loss Where No Direct Financial Loss Presents .....	849	86
i. Loss and the Sale of Adulterated Products.....	850	—
ii. Loss in Kickback Cases .....	853	—
e. Calculating the Loss .....	855	—
f. Offenses Otherwise Involving Sophisticated Means .....	860	87
g. Offenses Involving Multiple Victims or Mass Marketing .....	861	87
2. Role in the Offense.....	863	—
3. Use of a Special Skill.....	868	—
4. Abuse of a Position of Trust.....	871	87
a. General Application.....	872	—
b. Abuse of Trust and the Necessity of a License .....	879	—
5. Taking Advantage of Vulnerable Victims .....	881	—
6. Reckless Endangerment .....	885	—
7. Obstruction of Justice .....	887	—
B. Sentence Reductions.....	889	—
1. Minimal Role in the Offense.....	889	—
2. Acceptance of Responsibility .....	889	—
C. Sentences Outside the Guideline Sentencing Range.....	891	—
1. Departures .....	891	—
a. Upward Departures.....	892	—
b. Downward Departures.....	895	—
i. Collateral Consequences and Prior Good Works .....	897	—
ii. Diminished Capacity.....	901	—
2. Deviations from the Guideline Sentencing Range .....	902	—

	<u>Main Volume</u>	<u>Supple- ment</u>
a. “The Nature and Circumstances of the Offense” .....	904	—
b. The “History and Characteristics” of the Defendant.....	904	—
c. The Need for the Sentence Imposed to Meet Certain Specified Criteria .....	905	—
d. Additional Factors Under 18 U.S.C. §3553 ...	906	—
D. Financial Consequences .....	907	—
1. Fine .....	907	—
2. Restitution .....	908	—
E. Unusual Sentences.....	909	—
IV. The Sentencing of Organizations .....	911	—
A. Principles Guiding Federal Sentencings.....	912	—
1. Remedy the Harm .....	913	—
2. Determine the Fine Range .....	915	—
a. Determining the Fine Within the Range .....	917	—
b. Payment of the Fine.....	918	—
3. Impose Probation .....	919	—
B. Assessing Costs of the Prosecution .....	921	—
V. Conclusion .....	921	—
<b>APPENDIX LIST .....</b>	<b>923</b>	<b>89</b>
Appendix A Civil False Claims Act (31 U.S.C. §§3729–3733) .....	925	—
Appendix B Criminal Penalties for Acts Involving Federal Health Care Programs (42 U.S.C. §1320a-7b) (includes Anti-kickback Statute, 42 U.S.C. §1320a-7b(b)) [Replaces Appendix B in the Main Volume].....	943	91
Appendix C Stark Self-Referral Law (42 U.S.C. §1395nn)...	949	—
Appendix D Social Security Act–U.S. Code Correspondence Table: Selected Provisions Relating to Health Care Fraud.....	965	—
Appendix E Exclusion From Participation in Government Health Care Programs (42 U.S.C. §1320a-7) and Civil Monetary Penalties (42 U.S.C. §1320a-7a) [Replaces Appendix E in the Main Volume].....	967	97
Appendix F Selected Text From Privacy Regulations (Department of Health and Human Services): Disclosure of Patient Information (45 C.F.R. §164.512) .....	987	—

*Detailed Table of Contents*

xxxvii

	<u>Main Volume</u>	<u>Supple- ment</u>
Appendix G Table 11-A: Health Care Fraud Settlements of at Least \$1 Million (January 1, 1991– June 30, 2018) [Replaces Appendix G in the Main Volume].....	991	117
Table of Cases .....	1287	517
Index .....	1325	—